Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME.
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.
Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M, Chiu MN, Pilkhwal Sah S.
Cutan Ocul Toxicol. 2022 Mar;41(1):73-90. doi: 10.1080/15569527.2022.2034842. Epub 2022 Feb 20.
What Is New in Cutaneous T Cell Lymphoma?
Morgenroth S, Roggo A, Pawlik L, Dummer R, Ramelyte E.
Curr Oncol Rep. 2023 Nov;25(11):1397-1408. doi: 10.1007/s11912-023-01464-8. Epub 2023 Oct 24.
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M.
J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. doi: 10.1016/j.jaad.2020.04.105. Epub 2020 Apr 29.
Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment.
Rook AH, Rook KA, Lewis DJ.
Adv Exp Med Biol. 2021;1290:111-127. doi: 10.1007/978-3-030-55617-4_8.
Pruritus in Cutaneous T-Cell Lymphoma and Its Management.
Serrano L, Martinez-Escala ME, Zhou XA, Guitart J.
Dermatol Clin. 2018 Jul;36(3):245-258. doi: 10.1016/j.det.2018.02.011.
Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations.
Jahnke MN, O'Haver J, Gupta D, Hawryluk EB, Finelt N, Kruse L, Jen M, Horii KA, Frieden IJ, Price H, Coughlin CC.
Pediatrics. 2021 Dec 1;148(6):e2021051536. doi: 10.1542/peds.2021-051536.
Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.
Hu M, Scheffel J, Frischbutter S, Steinert C, Reidel U, Spindler M, Przybyłowicz K, Hawro M, Maurer M, Metz M, Hawro T.
Clin Exp Med. 2024 Jul 28;24(1):171. doi: 10.1007/s10238-024-01407-y.
[Mastocytosis in children].
Wassmer H, Hartmann K.
Dermatologie (Heidelb). 2023 May;74(5):323-329. doi: 10.1007/s00105-023-05168-9.
Malignancy-associated pruritus.
Rowe B, Yosipovitch G.
Eur J Pain. 2016 Jan;20(1):19-23. doi: 10.1002/ejp.760. Epub 2015 Sep 28.
